The estimated Net Worth of Michael J. Farrell is at least $133 million dollars as of 9 September 2024. Mr. Farrell owns over 14,683 units of Resmed stock worth over $121,111,248 and over the last 14 years he sold RMD stock worth over $1,626,954. In addition, he makes $10,429,800 as Chief Executive Officer et Director at Resmed.
Michael has made over 88 trades of the Resmed stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 14,683 units of RMD stock worth $1,247,761 on 9 September 2024.
The largest trade he's ever made was exercising 32,437 units of Resmed stock on 3 February 2012 worth over $503,422. On average, Michael trades about 3,625 units every 29 days since 2010. As of 9 September 2024 he still owns at least 478,852 units of Resmed stock.
You can see the complete history of Mr. Farrell stock trades at the bottom of the page.
Michael J. Farrell serves as Chief Executive Officer, Director of the Company. Mr. Farrell worked in management consulting, biotechnology, chemicals, and metals manufacturing at companies including Arthur D. Little, Sanofi Genzyme, DowDuPont, and BHP Billiton. Mr. Farrell serves on the board of directors of ResMed, the Advanced Medical Technology Association (AdvaMed) and Zimmer Biomet (NYSE: ZBH), a multibillion dollar public company that provides implantable musculoskeletal medical devices for patients globally. He is a member of two committees at Zimmer Biomet: nominating and governance; as well as compensation and management development. He also volunteers as a trustee for non-profit organizations: UC San Diego Foundation; Rady Children’s Hospital; and Father Joe’s Villages in San Diego, California. Mr. Farrell holds a bachelor of engineering with first-class honors from the University of New South Wales, a master of science in chemical engineering from the Massachusetts Institute of Technology, and a master of business administration from the MIT Sloan School of Management. Mr. Farrell’s skills and 20 years’ experience with ResMed and over 24 years’ experience with healthcare and manufacturing industries provides him with a unique and deep understanding of our operations, technology, and market, and led the board to the conclusion that he should serve as a director. In addition, the board believes it appropriate for the chief executive officer to serve as a member of the board.
As the Chief Executive Officer et Director of Resmed, the total compensation of Michael Farrell at Resmed is $10,429,800. There are no executives at Resmed getting paid more.
Michael Farrell is 48, he's been the Chief Executive Officer et Director of Resmed since 2013. There are 19 older and 2 younger executives at Resmed. The oldest executive at Resmed Inc. is Dr. Peter C. Farrell A.M., AM, B.E., BE (Hons), Ph.D., ScD, 79, who is the Founder & Non-Exec. Chairman.
Michael's mailing address filed with the SEC is 345, East Main Street, Warsaw, Kosciusko County, Indiana, 46580, United States.
Over the last 22 years, insiders at Resmed have traded over $250,830,262 worth of Resmed stock and bought 10,000 units worth $424,500 . The most active insiders traders include Peter C Farrell, Gary W Pace et David Pendarvis. On average, Resmed executives and independent directors trade stock every 7 days with the average trade being worth of $3,005,701. The most recent stock trade was executed by Brett Sandercock on 9 September 2024, trading 1,000 units of RMD stock currently worth $246,420.
at resmed (nyse: rmd, asx: rmd) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. our cloud-connected medical devices transform care for people with sleep apnea, copd and other chronic diseases. our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. by enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries.
Resmed executives and other stock owners filed with the SEC include: